peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

ghrelin agonist

Anamorelin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

Pharmacokinetics

Equilibrium dialysis in whole dog plasma at 37C for >5hrs measured PPB = 93.67% for CHEMBL2110579, indicating high protein binding in this matrix.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: PPB 93.67 %
Reported result
93.67 %
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Standard result: PPB 93.67 %”

    ChEMBL activities for CHEMBL2110579 · Activity 14764121

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91

Pharmacokinetics

Using equilibrium dialysis in whole rat plasma at 37C for >5hrs, CHEMBL2110579 had PPB = 84.0%, indicating most compound was protein-bound under these conditions.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: PPB 84.0 %
Reported result
84.0 %
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Standard result: PPB 84.0 %”

    ChEMBL activities for CHEMBL2110579 · Activity 14762893

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91

Pharmacokinetics

Plasma protein binding (PPB) quantifies the fraction bound to plasma proteins; equilibrium dialysis in whole guinea pig plasma at 37C for >5hrs gave PPB = 78.01% for CHEMBL2110579.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: PPB 78.01 %
Reported result
78.01 %
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Standard result: PPB 78.01 %”

    ChEMBL activities for CHEMBL2110579 · Activity 14761980

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91

What has been studied?

What the evidence says.

Study findings

In a high content imaging assay of SARS-CoV-2 induced cytotoxicity in VERO-6 cells, CHEMBL2110579 produced 0.26% inhibition at 10 uM after 48 hours with 0.01 MOI exposure.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: Inhibition = 0.26 %[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: Inhibition = 0.26 %
Reported result
0.26 %
Source records
2
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Standard result: Inhibition = 0.26 %”

    ChEMBL activities for CHEMBL2110579 · Activity 20149874

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91
  2. supports · Source-backed record
    “Standard result: Inhibition = 0.26 %”

    ChEMBL activities for CHEMBL2110579 · Activity 22075510

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91

Study findings

Nearly half of patients discontinued anamorelin early (within 3 weeks) in this cohort.

Sources[6]pubmedPredictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study.43 (47.8%) patients discontinued anamorelin treatment within 3 weeks.
Reported result
43 (47.8%) discontinued within 3 weeks
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “43 (47.8%) patients discontinued anamorelin treatment within 3 weeks.”

    Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study. · RESULTS

    pubmed:42544527:b1a296d51cec:b1a296d51cec

Study findings

This reflects the exploratory nature of the study and limits the strength of causal or predictive conclusions.

Sources[5]pubmedGamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.The associations of low pre-treatment GGT and TG levels with an early increase in food intake should be interpreted as hypothesis-generating and warrant external validation.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The associations of low pre-treatment GGT and TG levels with an early increase in food intake should be interpreted as hypothesis-generating and warrant external validation.”

    Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia. · Abstract

    pubmed:42528246:f4375ac84290:f4375ac84290

Study findings

The primary endpoint operationalized early food-intake response as a ≥30% increase from baseline within a 14-day window using clinical-record documentation.

Sources[5]pubmedGamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.The primary outcome was a documented increase in food intake (defined as a ≥30% increase from baseline) within 14 days based on clinical records.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The primary outcome was a documented increase in food intake (defined as a ≥30% increase from baseline) within 14 days based on clinical records.”

    Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia. · Abstract

    pubmed:42528246:f4375ac84290:f4375ac84290

Study findings

In the evaluable subset, early food-intake response (per the study’s definition) was documented in 38/53, while 15/53 showed no increase.

Sources[5]pubmedGamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.Among the evaluable patients (n=53), an increase was documented in 38 patients, while 15 showed no increase;
Reported result
38/53 documented increase; 15/53 no increase
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Among the evaluable patients (n=53), an increase was documented in 38 patients, while 15 showed no increase;”

    Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia. · Abstract

    pubmed:42528246:f4375ac84290:f4375ac84290

Study findings

The study defined its primary endpoint as treatment continuation duration, a time-to-discontinuation measure of ongoing anamorelin use.

Sources[4]pubmedTrends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.The primary outcome was the duration of treatment continuation.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The primary outcome was the duration of treatment continuation.”

    Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation. · METHODS

    pubmed:42360910:8a49c697c75e:8a49c697c75e

Study findings

Treatment persistence after anamorelin initiation had a median time-to-discontinuation of 60 days in this cohort.

Sources[2]pubmedThree-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index.The median time-to-discontinuation was 60 days;
Reported result
median 60 days
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The median time-to-discontinuation was 60 days;”

    Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index. · RESULTS

    pubmed:42237597:220f2888bb54:220f2888bb54

Study findings

43 (47.8%) patients stopped anamorelin within 3 weeks.

Sources[6]pubmedPredictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study.43 (47.8%) patients discontinued anamorelin treatment within 3 weeks.
Reported result
43 (47.8%) discontinued within 3 weeks
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “43 (47.8%) patients discontinued anamorelin treatment within 3 weeks.”

    Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study. · RESULTS

    pubmed:42544527:b1a296d51cec:b1a296d51cec

Study findings

When the willingness-to-pay threshold is set to 7.5 million JPY/QALY, the model estimated a 63.7% probability that anamorelin is cost-effective.

Sources[3]pubmedCost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.At the 7.5 million JPY/QALY threshold, cost-effectiveness probabilities were 63.7% for anamorelin and 93.2% for olanzapine.
Reported result
63.7% at 7.5 million JPY/QALY
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “At the 7.5 million JPY/QALY threshold, cost-effectiveness probabilities were 63.7% for anamorelin and 93.2% for olanzapine.”

    Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan. · RESULTS

    pubmed:42240544:7c4274a151cd:7c4274a151cd

Study findings

In this retrospective cohort, 12-week treatment completion for anamorelin occurred in 36/89 eligible patients (40.4%), reflecting the observed completion proportion in the sample.

Sources[7]pubmedPredictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study.Of 89 eligible patients, 36 (40.4%) completed 12 wk of treatment.
Reported result
36/89 (40.4%) completed 12 wk
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Of 89 eligible patients, 36 (40.4%) completed 12 wk of treatment.”

    Predictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study. · Abstract

    pubmed:42578447:21d5ad7c820b:21d5ad7c820b

Study findings

Beyond the primary endpoint, the analysis included longitudinal (over-time) assessment of performance status (PS) among anamorelin recipients.

Sources[4]pubmedTrends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.Secondary evaluation focused on chronological changes in the PS.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Secondary evaluation focused on chronological changes in the PS.”

    Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation. · METHODS

    pubmed:42360910:8a49c697c75e:8a49c697c75e

Study findings

In a cell-based antiviral phenotypic assay (high content imaging), inhibition of SARS-CoV-2 induced cytotoxicity in Caco-2 cells was 0.22% at 10 uM after 48 hours for CHEMBL2110579.

Sources[1]chembl-activitiesChEMBL activities for CHEMBL2110579Standard result: Inhibition = 0.22 %
Reported result
0.22 %
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Standard result: Inhibition = 0.22 %”

    ChEMBL activities for CHEMBL2110579 · Activity 18833012

    chembl-activities:chembl2110579:6268a5c6ee91:6268a5c6ee91

Study findings

After initiating anamorelin, continuation for at least 84 days occurred in 16 patients (40.0%) in this cohort.

Sources[2]pubmedThree-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index.16 patients (40.0%) continued ≥84 days.
Reported result
16 patients (40.0%)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “16 patients (40.0%) continued ≥84 days.”

    Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index. · RESULTS

    pubmed:42237597:220f2888bb54:220f2888bb54

Study findings

For the cost-effectiveness model, outcomes were simulated over 60 months using 4-week cycles, totaling 65 cycles.

Sources[3]pubmedCost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.The time horizon was 60 months, with 4-week cycles (65 cycles).
Reported result
4-week cycles; 65 cycles
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The time horizon was 60 months, with 4-week cycles (65 cycles).”

    Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan. · METHODS

    pubmed:42240544:7c4274a151cd:7c4274a151cd

Study findings

Using an economic evaluation metric (ICER), anamorelin compared with placebo was estimated at 7 405 419 Japanese yen per quality-adjusted life year (JPY/QALY).

Sources[3]pubmedCost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.The incremental cost-effectiveness ratios were 7 405 419 Japanese yen (JPY)/QALY for anamorelin and 6 737 715 JPY/QALY for olanzapine compared with placebo.
Reported result
7 405 419 JPY/QALY
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The incremental cost-effectiveness ratios were 7 405 419 Japanese yen (JPY)/QALY for anamorelin and 6 737 715 JPY/QALY for olanzapine compared with placebo.”

    Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan. · RESULTS

    pubmed:42240544:7c4274a151cd:7c4274a151cd

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
  • 213 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (133), assurance_score_below_0.72 (62), current_regulatory_source_required (42), extraction_ambiguity (181), high_risk_requires_regulatory_or_two_independent_sources (77), no_direct_support (193), proposal_not_staged (11)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. ChEMBL activities for CHEMBL2110579 ↗

    chembl-activities · published 2026-08-25 · retrieved 2026-08-25T22:43:25Z

  2. Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-25T22:43:25Z

  3. Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan. ↗

    pubmed · published 2026-06-04 · retrieved 2026-08-25T22:43:25Z

  4. Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation. ↗

    pubmed · published 2026-06-26 · retrieved 2026-08-25T22:43:25Z

  5. Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia. ↗

    pubmed · published 2026-07-25 · retrieved 2026-08-25T22:43:25Z

  6. Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study. ↗

    pubmed · published 2026-08-03 · retrieved 2026-08-25T22:43:25Z

  7. Predictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study. ↗

    pubmed · published 2026-08-11 · retrieved 2026-08-25T22:43:25Z

Publication history and provenance

Version 3 · Automated assessment · 2026-08-25T22:43:25Z

fa3a450ff4a3da89291594def535fec55c7f7da87ae7cd7f72cf43874101d5fe